Inventor · disambiguated record
Angelika Fretzen
Also filed as: FRETZEN ANGELIKA
21 granted patents·43 pending applications·215 citations·filing 2003–2024
95Inventor score
Files withIRONWOOD PHARMACEUTICALS INC41CURRIE MARK G5FRETZEN ANGELIKA5FOREST LAB HOLDINGS LTD3MICROBIA INC2
Top patents by PatentIndex Score
64 records- 0195US7910546B2Methods and compositions for the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2008·Granted Mar 22, 2011·29 cites·28 claims
- 0295US7371727B2Methods and compositions for the treatment of gastrointestinal disordersMICROBIA INC·Filed 2004·Granted May 13, 2008·60 cites·6 claims
- 0393US7772188B2Methods and compositions for the treatment of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2005·Granted Aug 10, 2010·31 cites·10 claims
- 0492US8748442B2sGC stimulatorsKIM CHARLES·Filed 2011·Granted Jun 10, 2014·22 cites·79 claims
- 0591US9139564B22-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2012·Granted Sep 22, 2015·15 cites·6 claims
- 0690US8748573B2Formulations comprising linaclotideFRETZEN ANGELIKA·Filed 2010·Granted Jun 10, 2014·8 cites·10 claims
- 0787US9309235B2SGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2013·Granted Apr 12, 2016·12 cites·25 claims
- 0887US8507447B2Treatments for gastrointestinal disordersCURRIE MARK G·Filed 2010·Granted Aug 13, 2013·12 cites·30 claims
- 0986US8802628B2Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administrationFRETZEN ANGELIKA·Filed 2009·Granted Aug 12, 2014·7 cites·26 claims
- 1086US2025243177A1sGC STIMULATORSCYCLERION THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1185US2023346881A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1285US2023340025A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1383US2023310329A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1481US8946158B2Treatments of gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2013·Granted Feb 3, 2015·5 cites·35 claims
- 1581US8735360B2Treatments for gastrointestinal disordersCURRIE MARK G·Filed 2010·Granted May 27, 2014·5 cites·36 claims
- 1679US2025073301A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 1779US2022227812A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1879US2023272007A1Treatments for gastrointestinal disordersIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1979US2022233635A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2078US10675325B2Stable formulations of linaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Granted Jun 9, 2020·0 cites·18 claims
- 2178US2022125734A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 2276US8933030B2Treatments for gastrointestinal disordersFRETZEN ANGELIKA·Filed 2011·Granted Jan 13, 2015·2 cites·20 claims
- 2376US8779090B2Methods and compositions for the treatment of heart failure and other disordersZIMMER DANIEL·Filed 2008·Granted Jul 15, 2014·3 cites·1 claims
- 2475US10702576B2Stable formulations of linaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Granted Jul 7, 2020·0 cites·20 claims
- 2575US2021388026A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2675US2021290554A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2775US2023398173A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2874US9617305B2Treatments for gastrointestinal disordersCURRIE MARK G·Filed 2012·Granted Apr 11, 2017·1 cites·43 claims
- 2973US2023142270A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3071US2020283479A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3170US2022119452A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3270US2014287034A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3369US9657012B2FAAH inhibitorsHUDSON COLLEEN·Filed 2011·Granted May 23, 2017·3 cites·4 claims
- 3468US2020009216A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3566US2021032292A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3665US2019029967A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3764US2014378393A1Stable Formulations of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3864US2015094265A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3963US2019345130A1Sgc stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4063US2016310559A1Delayed Release Compositions of LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4162US2012009225A1Stable Solid Formulation of Therapeutic Polypeptides Suitable for Oral AdministrationFRETZEN ANGELIKA·Filed 2009·Application pending·0 cites
- 4261US2013273169A1Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationFOREST LAB HOLDINGS LTD·Filed 2013·Application pending·0 cites
- 4361US2014323448A1sGC STIMULATORSIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 4460US2013190239A1Formulations Comprising LinaclotideIRONWOOD PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 4560US2015132375A1Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral AdministrationIRONWOOD PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4659US2019062376A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4758US10189809B2SGC stimulatorsIRONWOOD PHARMACEUTICALS INC·Filed 2017·Granted Jan 29, 2019·0 cites·23 claims
- 4857US2018186835A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 4957US2014005128A1Treatments of gastrointestinal disordersMO YUN·Filed 2011·Application pending·0 cites
- 5057US2014256634A1Treatments for Gastrointestinal DisordersIRONWOOD PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Angelika Fretzen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →